1. Restenosis following percutaneous coronary arterial intervention: what should the clinician do in order to identify and treat this complication?

   • Joseph S. Alpert

   Editor's Commentary Pages: 391 - 392

2. Web alert

   News Pages: 393 - 394

3. Literature alert

   Abstract Pages: 395 - 399

4. Antihypertensive drugs and the kidney

   • Mitra K. Nadim
   • Renee Dua
   • Vito M. Campese

   OriginalPaper Pages: 403 - 408

5. Antihypertensive drugs and the heart

   • Joseph A. Diamond
   • Robert A. Phillips

   OriginalPaper Pages: 409 - 415

6. Hypertension in black patients: Special issues and considerations

   • Shawna D. Nesbitt

   OriginalPaper Pages: 416 - 420

7. Combination drug treatment of hypertension: Have we come full circle?

   • Addison A. Taylor

   OriginalPaper Pages: 421 - 426

8. Hypertension and the metabolic syndrome

   • John A. Farmer

   OriginalPaper Pages: 427 - 433

9. Clinical trials report

   • Peter W. F. Wilson

   OriginalPaper Pages: 437 - 438

10. Ezetimibe: A novel cholesterol-lowering agent that highlights novel physiologic pathways

    • Shailendra B. Patel

    OriginalPaper Pages: 439 - 442

11. Treatment of lipids and type 2 diabetes

    • Kathie L. Hermayer

    OriginalPaper Pages: 443 - 450

12. Hypothyroidism and dyslipidemia: Modern concepts and approaches

    • Elizabeth N. Pearce

    OriginalPaper Pages: 451 - 456

13. Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story

    • Emma A. Meagher

    OriginalPaper Pages: 457 - 463

14. Aggressive diets and lipid responses

    • Claudia Panzer
    • Caroline M. Apovian

    OriginalPaper Pages: 464 - 473